The U.S. Food and Drug Administration (FDA) has approved a fentanyl nasal spray (Lazanda®, Archimedes Pharma Ltd/Archimedes Pharma U.S. Inc) for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
This marks the first FDA product approval for Archimedes… Continue
Added by Peter Hofland, PhD on June 30, 2011 at 7:00pm —
During a U.S. Food and Drug Administration (FDA) hearing on Wednesday, the FDA’s Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of bevacizumab (Avastin®, Roche/Genentech) in combination with paclitaxel chemotherapy for previously untreated (first-line) HER2-negative… Continue
Added by Peter Hofland, PhD on June 30, 2011 at 1:30pm —
The European Commission has extended the existing bevacizumab (Avastin®, Roche/Genentech) metastatic breast cancer label to include combination with capecitabine (Xeloda®, Roche/Genentech). The… Continue
Added by Peter Hofland, PhD on June 30, 2011 at 11:30am —
Results of the National Lung Screening Trial (NLST), published today in the New England Journal of Medicine, showed that lung cancer deaths fell by 20% and all-cause mortality fell by 7% when heavy smokers were screened regularly using low-dose spiral computed tomography (CT) compared with standard chest x-ray. The NLST study followed more than 53,000 current and former smokers ages 55-74.
"Lung cancer is the… Continue
Added by Peter Hofland, PhD on June 30, 2011 at 1:30am —
Scientists have found a 20% percent reduction in deaths from lung cancer among current or former heavy smokers who were screened with low-dose helical computed tomography (CT) versus those screened by chest X-ray. The primary research results from the National Lung Screening Trial (NLST) were published online today in the New England Journal of Medicine.
This article provides a… Continue
Added by Peter Hofland, PhD on June 29, 2011 at 8:30pm —
Scientists have begun to reveal the order of the genetic aberrations in individual cancers in a finding they say is key to early diagnosis and personalized medicine.
“We know that each cancer is a collection of genetic malfunctions,” said Raymond Cho, Ph.D., an assistant clinical professor in the department of dermatology at the University of California, San Francisco (UCSF). “We now show it is possible to determine which changes happen earlier and which ones… Continue
Added by Peter Hofland, PhD on June 29, 2011 at 7:30pm —
Patients treated with sunitinib (Sutent®, Pfizer Oncology) and sorafenib (Nexavar®, Bayer Healthcare/Onxy Pharmaceuticals) responded to the flu vaccine, which suggests… Continue
Added by Peter Hofland, PhD on June 28, 2011 at 10:00pm —
A multi-center phase II study will evaluate farletuzumab (Morphotek, Inc., a subsidiary of Eisai Inc), a monoclonal antibody that specifically binds to folate receptor-alpha (FRA), in adenocarcinoma of the lung, a type of non-small cell lung cancer (NSCLC), in combination with the physician's choice of one of three standard platinum-containing doublets that are approved and… Continue
Added by Peter Hofland, PhD on June 28, 2011 at 6:30am —
European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for brentuximab vedotin (Adcetris™, Takeda Pharmaceutical and Millennium: The Takeda Oncology Company) for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). The Marketing Authorization Application was filed by Takeda Global Research &… Continue
Added by Peter Hofland, PhD on June 27, 2011 at 2:00pm —
Findings from the Childhood Cancer Survivor Study led by investigators at St. Jude Children's Research Hospital identify new cancer risks when survivors of childhood cancers become adults. The results of the study underscores the importance of regular cancer screenings.
The largest study yet of adult childhood cancer survivors found that the first cancer is just the beginning of a lifelong battle against… Continue
Added by Peter Hofland, PhD on June 27, 2011 at 1:30pm —
Recent findings published in Leukemia Research show that the experimental therapeutic leukotoxin (Leukothera™; LtxA; Actinobac Biomed, Inc) which binds to the leukocyte function antigen (LFA-1) on white blood cells (WBCs) and induces cell death via apoptosis or necrosis, combined with standard anti-leukemia agents, offers synergistic anti-leukemia effects.
The outcome of these in vitro… Continue
Added by Peter Hofland, PhD on June 27, 2011 at 10:30am —
Results from a nationwide research poll released today by the Colon Cancer Alliance and Quest Diagnostics suggest that one in three of men and women age 60-70 who have been screened for colon cancer have done so only once, suggesting a failure to follow medical guidelines that call for periodic testing after initial screening at age 50 by colonoscopy and other… Continue
Added by Peter Hofland, PhD on June 27, 2011 at 10:30am —
A rapid and aggressive spread into surrounding tissue, resistance to standard chemotherapy and a tendency to recur make pancreatic cancer one of the most challenging diseases to treat. The disease is also difficult to diagnose in its early stage, and patients usually present with incurable disease. It has a high mortality rate, and so far no therapy has been shown to significantly impact survival. Pancreatic cancer is considered an orphan cancer, because of its relatively… Continue
Added by Peter Hofland, PhD on June 27, 2011 at 6:30am —
Enrollment of patients in a Phase I clinical trial with Graspa® in pancreatic cancer has been completed. This product contains the enzyme L-asparaginase encapsulated in red blood cells. The technology for encapsulating asparaginase was developed by Erytech Pharma
The first results in this study demonstrated that Graspa was active, with a safety profile that was satisfactory for patients in last-line… Continue
Added by Peter Hofland, PhD on June 27, 2011 at 6:00am —
Researchers at Omeros Corporation, a clinical-stage biopharmaceutical company, have identified compounds that interact with orphan G protein-coupled receptors (GPCRs) P2Y8 and OPN4. P2Y8 (also known as P2RY8) is associated with acute lymphoblastic leukemia (ALL), an aggressive cancer of the white blood cells. ALL is the most common type of malignancy diagnosed in children. Continue
The OPN4 receptor is involved with regulation of circadian rhythms, and could…
Added by Peter Hofland, PhD on June 27, 2011 at 4:30am —
The investigational agent aflibercept (Zaltrap™/AVE0005, Sanofi Aventis and Regeneron Pharmaceuticals, Inc), also known as VEGF Trap, significantly improved survival in previously treated metastatic colorectal cancer patients. Results from Pivotal Phase III VELOUR Trial, presented at the ESMO World Congress on… Continue
Added by Peter Hofland, PhD on June 25, 2011 at 4:30pm —
Epoetin alfa (Epogen®, Procrit®)was initially approved by the U.S. Food and Drug Administration (FDA) in 1989 to treat some forms of anemia resulting from chronic kidney disease (CKD). It also is used to treat anemia in patients with HIV infection who are receiving zidovudine (Retrovir®)and in… Continue
Added by Peter Hofland, PhD on June 24, 2011 at 7:00pm —
Pre-clinical research results presented at the European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer in Barcelona, Spain shows that novel Focal Adhesion Kinase (FAK) inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) decrease pancreatic cancer tumor blood flow and reduce blood vessel density in vivo. The research was conducted by scientists of… Continue
Added by Peter Hofland, PhD on June 23, 2011 at 5:30pm —
Harnessing the new generation of rapid, highly accurate gene-sequencing techniques, a research team has identified the disease-causing mutation in a newly characterized rare genetic disease, by analyzing DNA from just a few individuals. The power and speed of the innovative bioinformatics tool marks a step toward personalized genomics—discovering causative mutations in individual patients.
"Our research is proof-of-principle that a new software tool called… Continue
Added by Peter Hofland, PhD on June 23, 2011 at 10:00am —
A treatment that has virtually no side effects has been found to be an effective weapon for fighting early-stage breast cancer, according to results of a clinical trial conducted at Loma Linda University Medical Center.
Results of the Phase II clinical trial conducted by researchers at Loma Linda University Medical Center Department of Radiation Medicine indicate that partial breast radiotherapy… Continue
Added by Peter Hofland, PhD on June 22, 2011 at 11:00am —